Skip to content

Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization

Prevalence of Renal Artery Stenosis in Patients Refered for Cardiac Catheterization to Heart Center Hospital in July-September 2008

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00885768
Acronym
RAS
Enrollment
146
Registered
2009-04-22
Start date
2008-07-31
Completion date
2009-04-30
Last updated
2011-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Artery Stenosis

Keywords

RAS(renal Artery Stenosis), Atherosclerosis, angiography

Brief summary

All patients referred for coronary angiography will simultaneously be evaluated for renal artery stenosis and then stenosis more than 50% will be analyzed according to clinical conditions, risk factors and lab data.

Detailed description

Renal Artery Stenosis (RAS) is a common finding in patients with generalized atherosclerosis. It is the cause of 15-20% of end stage renal disease in elderly patients. The prevalence of asymptomatic RAS in general population is unknown but it estimated to be 18% in 7th decade and more than 50% in the 8th. It is critical to find and manage the RAS before it's symptoms appear. The Gold standard for diagnosis of atherosclerotic arterial stenosis is angiography. In this study we will evaluate the prevalence, severity, location and related factors to renal artery stenosis in patients whom referred for coronary angiography in period of July-September in one of the most referral heart center in Iran, The Tehran heart center which is doing more than 50 coronary angiography daily.

Interventions

PROCEDUREangiography

all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.

Sponsors

Tehran Heart Center
CollaboratorOTHER
Imam Khomeini Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age more than 18 years

Exclusion criteria

* contraindication to contrast use * not signing consent

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Renal Artery Stenosis (RAS)2 months
The Number of Patients With Renal Artery Stenosis3monthsthe prevalence of renal artery stenosis in patients with coronary artery disease

Countries

Iran

Participant flow

Recruitment details

all patients recruited during 4 months from April 2008 through July 2008 in Tehran Heart Center.

Participants by arm

ArmCount
Renal Artery Stenosis
the patients with coronary artery stenosis who have also renal artery stenosis
146
Total146

Baseline characteristics

CharacteristicRenal Artery Stenosis
Age Continuous61.17 years
STANDARD_DEVIATION 9.47
Region of Enrollment
Iran, Islamic Republic of
146 participants
Sex: Female, Male
Female
51 Participants
Sex: Female, Male
Male
95 Participants
the adult patients with coronary artry disease
<=18 years
0 participants
the adult patients with coronary artry disease
>=65 years
19 participants
the adult patients with coronary artry disease
Between 18 and 65 years
127 participants
the patients with coronary artery disease146 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 12
serious
Total, serious adverse events
0 / 5

Outcome results

Primary

Prevalence of Renal Artery Stenosis (RAS)

Time frame: 2 months

Primary

The Number of Patients With Renal Artery Stenosis

the prevalence of renal artery stenosis in patients with coronary artery disease

Time frame: 3months

ArmMeasureValue (NUMBER)
Renal Artery StenosisThe Number of Patients With Renal Artery Stenosis146 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026